FI844934A0 - Förfarande för framställning av rekombinant gammainterferon med förbättrad stabilitet vektor och DNA utnyttjade vid förfarandet - Google Patents

Förfarande för framställning av rekombinant gammainterferon med förbättrad stabilitet vektor och DNA utnyttjade vid förfarandet

Info

Publication number
FI844934A0
FI844934A0 FI844934A FI844934A FI844934A0 FI 844934 A0 FI844934 A0 FI 844934A0 FI 844934 A FI844934 A FI 844934A FI 844934 A FI844934 A FI 844934A FI 844934 A0 FI844934 A0 FI 844934A0
Authority
FI
Finland
Prior art keywords
vector
gamma interferon
improved stability
producing recombinant
dna used
Prior art date
Application number
FI844934A
Other languages
English (en)
Finnish (fi)
Other versions
FI844934L (sv
FI91884B (sv
FI91884C (sv
Inventor
Patrick William Gray
Ernst Heinrich Rinderknecht
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27072811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI844934(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of FI844934A0 publication Critical patent/FI844934A0/sv
Publication of FI844934L publication Critical patent/FI844934L/sv
Publication of FI91884B publication Critical patent/FI91884B/sv
Application granted granted Critical
Publication of FI91884C publication Critical patent/FI91884C/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/811Interferon
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/14Lymphokine; related peptides
    • Y10S930/142Interferon
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/30Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
FI844934A 1983-12-16 1984-12-13 Förfarande för framställning av rekombinant gammainterferon med förbättrad stabilitet vektor och DNA utnyttjade vid förfarandet FI91884C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56200983A 1983-12-16 1983-12-16
US56200983 1983-12-16
US58421784 1984-02-27
US06/584,217 US4855238A (en) 1983-12-16 1984-02-27 Recombinant gamma interferons having enhanced stability and methods therefor

Publications (4)

Publication Number Publication Date
FI844934A0 true FI844934A0 (sv) 1984-12-13
FI844934L FI844934L (sv) 1985-06-17
FI91884B FI91884B (sv) 1994-05-13
FI91884C FI91884C (sv) 1994-08-25

Family

ID=27072811

Family Applications (1)

Application Number Title Priority Date Filing Date
FI844934A FI91884C (sv) 1983-12-16 1984-12-13 Förfarande för framställning av rekombinant gammainterferon med förbättrad stabilitet vektor och DNA utnyttjade vid förfarandet

Country Status (23)

Country Link
US (4) US4855238A (sv)
EP (1) EP0146354B2 (sv)
JP (6) JPH0789935B2 (sv)
KR (1) KR940008978B1 (sv)
AT (1) ATE135405T1 (sv)
AU (1) AU597872B2 (sv)
CA (1) CA1341573C (sv)
CY (1) CY1945A (sv)
DE (1) DE3486424T3 (sv)
DK (1) DK166832B1 (sv)
ES (1) ES8801553A1 (sv)
FI (1) FI91884C (sv)
GR (1) GR82468B (sv)
HK (1) HK175996A (sv)
HU (1) HU202278B (sv)
IE (1) IE72494B1 (sv)
IL (1) IL73803A (sv)
LV (1) LV11633B (sv)
MY (1) MY102899A (sv)
NO (1) NO178789C (sv)
OA (1) OA07902A (sv)
PH (1) PH24790A (sv)
PT (1) PT79691A (sv)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
GB8406910D0 (en) * 1984-03-16 1984-04-18 Biogen Nv Gamma interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
JPS60172999A (ja) * 1983-12-20 1985-09-06 Suntory Ltd 新規な塩基性ポリペプチドおよびその製造法
DK168016B1 (da) * 1983-12-26 1994-01-17 Kyowa Hakko Kogyo Kk Derivat af humant interferon-gamma-polypeptid
EP0318765A1 (en) * 1984-03-16 1989-06-07 Biogen, Inc. A modified gamma interferon dna sequences encoding it and process for producing it
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
CA1302320C (en) * 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
JPS61108397A (ja) * 1984-10-31 1986-05-27 Green Cross Corp:The インタ−フエロン−γ蛋白質の製造法
JPS6156195A (ja) * 1985-03-01 1986-03-20 Asahi Chem Ind Co Ltd 新規生理活性ペプチド
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
ATE81675T1 (de) * 1985-04-30 1992-11-15 Takeda Chemical Industries Ltd Produktion eines proteins.
DE3532134A1 (de) * 1985-09-10 1987-03-12 Basf Ag Verfahren zur herstellung von proteinen bestimmter n-terminaler struktur mit hilfe von prokaryonten
DE3536939A1 (de) * 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
ATE132534T1 (de) * 1986-08-01 1996-01-15 Commw Scient Ind Res Org Rekombinanter impfstoff
GB8619725D0 (en) * 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments
US5157004A (en) * 1986-12-27 1992-10-20 Takeda Chemical Industries, Ltd. Polypeptides and production thereof
JP2653061B2 (ja) * 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法
DE3730331A1 (de) * 1987-09-10 1989-03-30 Basf Ag Neue polypeptide, verfahren zur herstellung, die vektoren dafuer und arzneimittel daraus
AT393690B (de) * 1987-10-08 1991-11-25 Hoffmann La Roche Homogene, rekombinante immun-interferonfragmente
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
ATE198353T1 (de) * 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
BG52073B2 (en) * 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
EP0546099B1 (en) * 1990-08-31 1994-10-12 Schering Corporation Use of human Interferon gamma 4-134
DE4036856C1 (sv) * 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5227158A (en) * 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
AU7116394A (en) * 1993-07-01 1995-01-24 Merck & Co., Inc. Culture medium for recombinant yeasts
TW249202B (sv) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1012184B1 (en) 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
AU757910B2 (en) 1998-04-02 2003-03-13 Genentech Inc. Treatment of cardiac hypertrophy
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
RU2140285C1 (ru) * 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
WO2000071716A2 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
CA2373822A1 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor variants
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
EP2267026A1 (en) 2000-04-12 2010-12-29 Human Genome Sciences, Inc. Albumin fusion proteins
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
EP1351707B9 (en) * 2001-01-09 2012-01-25 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
AU2002342163B2 (en) * 2001-11-06 2007-11-08 Laboratoires Serono Sa Methods of treating endometreosis
WO2003039466A2 (en) * 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Method of treating estrogen responsive breast cancer
NZ532779A (en) * 2001-11-09 2008-04-30 Intarcia Therapeutics Inc Method for treating diseases with omega interferon
EP1461067A1 (en) * 2001-12-07 2004-09-29 Intermune, Inc. Compositions and method for treating hepatitis virus infection
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
CA2491178A1 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP2390262A1 (en) 2003-05-16 2011-11-30 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
EP2407470A3 (en) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2006141263A (ja) * 2004-11-18 2006-06-08 Kyoto Univ (r)−ヒドロキシニトリルリアーゼの製造方法
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR20080019606A (ko) * 2005-05-04 2008-03-04 나우틸루스 바이오텍 변형된 인터페론-감마 폴리펩티드 및 변형된 인터페론-감마폴리펩티드를 사용하는 방법
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8617531B2 (en) * 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8243103B2 (en) * 2009-05-29 2012-08-14 Exelis, Inc. Laser aiming spot distinguishing methods and apparatus
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
CA2788607C (en) * 2010-02-01 2018-03-20 Digna Biotech,S.L. Process for the production of interferon alpha 5
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
EP3388835B1 (en) 2012-05-16 2020-04-01 Immune Design Corp. Vaccines for hsv-2
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP4112638A1 (en) 2016-05-16 2023-01-04 Access to Advanced Health Institute Formulation containing tlr agonist and methods of use
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
MX2018014399A (es) 2016-06-01 2019-06-06 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
AU2018321893A1 (en) 2017-08-23 2020-03-19 Wayne State University In vivo immunoimaging of interferon-gamma
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
KR20230013021A (ko) 2020-03-19 2023-01-26 트리젤 엘티디. 온도-반응성 바이러스 저장 시스템
EP4125998A1 (en) 2020-03-30 2023-02-08 Trizell Ltd. Compositions and methods for treating cancer

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
NL7404590A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het reactiveren van interferon.
US4332892A (en) * 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4460685A (en) * 1980-05-29 1984-07-17 New York University Method of enhancing the production of human γ Interferon
US4311639A (en) * 1980-07-25 1982-01-19 E. I. Du Pont De Nemours And Company Immunogenic interferon peptides
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
FI64813C (fi) * 1980-12-31 1984-01-10 Ilkka Antero Palva Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
US4382027A (en) * 1981-08-18 1983-05-03 Meloy Laboratories, Inc. Purification of human immune interferon
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
ZA831094B (en) * 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
ZA83768B (en) * 1982-03-01 1983-10-26 Hoffmann La Roche Homogeneous human immune interferon and process therefor
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
IL69851A0 (en) * 1982-09-30 1983-12-30 Japan Found Cancer Novel dna and recombinant plasmid containing the same
WO1984002129A1 (en) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPH0740925B2 (ja) * 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
JPS59169494A (ja) * 1983-03-17 1984-09-25 Takeda Chem Ind Ltd 新規組み換えdnaおよびその用途
US4599306A (en) * 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
ZA844082B (en) * 1983-06-01 1985-09-25 Hoffmann La Roche Polypeptides having interferon activity
IL72773A0 (en) * 1983-08-29 1984-11-30 Meloy Lab Production of immune interferon and its mrna
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
JPS6079000A (ja) * 1983-10-04 1985-05-04 Takeda Chem Ind Ltd ヒトγ型インタ−フエロン単量体の製造法
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
JPS60118196A (ja) * 1983-11-30 1985-06-25 Takeda Chem Ind Ltd インタ−フェロンの製造法
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
JP2653061B2 (ja) 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法

Also Published As

Publication number Publication date
JPH0789935B2 (ja) 1995-10-04
CA1341573C (en) 2008-05-13
LV11633A (lv) 1996-12-20
OA07902A (en) 1986-11-20
US6497871B1 (en) 2002-12-24
EP0146354B2 (en) 2001-10-24
ES8801553A1 (es) 1988-02-16
PT79691A (en) 1985-01-01
JPH0794477B2 (ja) 1995-10-11
JPH0919295A (ja) 1997-01-21
NO178789C (no) 1996-06-05
IL73803A0 (en) 1985-03-31
EP0146354A2 (en) 1985-06-26
US5574137A (en) 1996-11-12
ES538620A0 (es) 1988-02-16
PH24790A (en) 1990-10-30
IL73803A (en) 1997-09-30
HUT36187A (en) 1985-08-28
US4855238A (en) 1989-08-08
MY102899A (en) 1993-03-31
JP2580491B2 (ja) 1997-02-12
NO178789B (no) 1996-02-26
EP0146354A3 (en) 1986-03-19
IE843203L (en) 1985-06-16
NO845042L (no) 1985-06-17
AU597872B2 (en) 1990-06-14
HU202278B (en) 1991-02-28
AU3663584A (en) 1985-06-20
US5595888A (en) 1997-01-21
HK175996A (en) 1996-09-27
LV11633B (en) 1997-08-20
DE3486424T2 (de) 1996-09-12
JP2719128B2 (ja) 1998-02-25
JPH10210985A (ja) 1998-08-11
JPH08151399A (ja) 1996-06-11
DK166832B1 (da) 1993-07-19
GR82468B (en) 1985-03-27
IE72494B1 (en) 1997-04-23
FI844934L (sv) 1985-06-17
KR850004273A (ko) 1985-07-11
DK600984D0 (da) 1984-12-14
FI91884B (sv) 1994-05-13
ATE135405T1 (de) 1996-03-15
FI91884C (sv) 1994-08-25
EP0146354B1 (en) 1996-03-13
DE3486424D1 (de) 1996-04-18
DK600984A (da) 1985-08-22
KR940008978B1 (ko) 1994-09-28
CY1945A (en) 1984-12-14
JP2545206B2 (ja) 1996-10-16
DE3486424T3 (de) 2002-06-06
JPH03201979A (ja) 1991-09-03
JPS60202899A (ja) 1985-10-14
JP2886145B2 (ja) 1999-04-26
JPH07173196A (ja) 1995-07-11

Similar Documents

Publication Publication Date Title
FI844934A0 (sv) Förfarande för framställning av rekombinant gammainterferon med förbättrad stabilitet vektor och DNA utnyttjade vid förfarandet
ES8802235A1 (es) Procedimiento para preparar un polipeptido
LU88327I2 (fr) Interferon gamma-1b (Imukin /Immukine)
FI19992064A (sv) Förfarande för framställning av erythropoietin
DE10399037I2 (de) Rekombinante Virusproteine begleitet von lymphadenopathischem Sydrom und/oder "Acquired Immune Deficiency Syndrome" (AIDS).
YU47735B (sh) Postupak za sintezu biološki aktivnih polipeptida limfotoksina
GR79236B (sv)
DE3681551D1 (de) Menschlicher granulozyten-colony stimulierender faktor.
ATE44652T1 (de) Zubereitung mit gehalt an stabilisiertes polypeptid mit gamma-interferon aktivitaet.
DK619086A (da) Gm-csf-protein, derivater deraf, samt fremstilling og anvendelse af saadanne proteiner
ATE46348T1 (de) Neue, physiologisch aktive polypeptide und deren herstellungsverfahren.
DE69106407D1 (de) Verfahren zur Herstellung von rekombinantem menschlichem gamma-Interferon ohne Cystein und ohne Methionin am N-Terminal.

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: GENENTECH, INC.